Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Published:2015-11-26 Issue:22 Volume:373 Page:2117-2128
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Zinman Bernard,Wanner Christoph,Lachin John M.,Fitchett David,Bluhmki Erich,Hantel Stefan,Mattheus Michaela,Devins Theresa,Johansen Odd Erik,Woerle Hans J.,Broedl Uli C.,Inzucchi Silvio E.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1504720

Cited by 8910 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Accelerometer-measured physical activity in patients with heart failure and reduced ejection fraction: Determinants and relationship with patient-reported health status;American Heart Journal;2024-12

2. Inibidores de SGLT2 e inflamassoma NLRP3: alvo potencial na doença renal do diabetes;Brazilian Journal of Nephrology;2024-12

3. SGLT2 inhibitors and NLRP3 inflammasome: potential target in diabetic kidney disease;Brazilian Journal of Nephrology;2024-12

4. The role of bone in energy metabolism: A focus on osteocalcin;Bone;2024-11

5. Investigating the research trajectory and future trends of immune disorders in diabetes cardiovascular complications: A bibliometric analysis over the past decade based on big data;Ageing Research Reviews;2024-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP